Antiserum Arsenal: Strengthening the Fight Against Rabies.
Introduction Rabies remains a serious zoonotic disease caused by Lyssaviruses. Though vaccines are available for prevention of rabies in humans as well as animals, rabies antiserum plays an important supportive role in the management of rabies especially in developing nations. This article aims to provide an overview of rabies antiserum - its various applications, production process, mechanism of action and effectiveness.
Post-exposure Prophylaxis Rabies antiserum is an integral part of post-exposure prophylaxis (PEP) along with vaccination for category III exposures as recommended by the World Health Organization. It is administered through infiltration and intraneural routes at and around the wound along with vaccines. This helps in neutralizing any virus present at the site of exposure and prevents its entry into the central nervous system, buying time for the active immunization to work. Its role is crucial in immunocompromised individuals and children for whom cellular immune response may be delayed.
Pre-exposure Prophylaxis Some occupational groups such as veterinarians, animal handlers etc. who are at continuous risk of unapparent exposure can take antiserum alone as pre-exposure prophylaxis. The antibody levels achieved provide immediate protection until an active immune response develops following natural exposure or booster doses. However, vaccination should still be taken at the earliest opportunity to ensure sustained protection.
Production and Mechanism of Action Rabies antiserum is a pathogen-specific immunoglobulin preparation containing high titres of rabies virus-neutralizing antibodies. It is manufactured by hyperimmunizing horses/sheep with inactivated rabies virus. The neutralizing antibody content is standardized and purified from the antiserum. Upon infiltration around wounds, the antibodies bind to free virus particles, aggregates or soluble antigens thereby preventing viral attachment and entry into host cells. This passive transfer of immunity helps clear or control initial infection bought about by cell-associated virus.
Effectiveness and Limitations Several clinical studies and reports of PEP failures have demonstrated the effectiveness of antiserum in preventing rabies when used in combination with adequate wound treatment and full vaccination regimen. However, there are certain practical limitations to its usage. Production relies on large animals and is less sustainable. The short half-life requires repeat dosing and careful scheduling with vaccinations. Storage and maintenance of cold chain during transport adds to Logistic challenges especially in remote regions.
Recent Advances Newer purification techniques enable higher yields and more standardized product quality. Cell culture technologies can eliminate animal usage altogether. A human monoclonal antibody cocktail is being evaluated as alternative to equine antiserum post-exposure. Research also aims at improving stability and extending half-life of antibodies through molecular engineering and nanoparticle conjugation. Such advances hold promise to enhance availability, effectiveness and compliance to rabies biologics especially in resource-limited settings.
Conclusion In summary, rabies antiserum remains a valuable adjunct to rabies vaccination in post and pre-exposure rabies prophylaxis despite facing some practical constraints. Continuous efforts to improve production technologies, antibody formulations and develop substitutes are expected to help bolster rabies control programs worldwide in future.